Trial Profile

A Randomized, Double-blind, Placebo-controlled Phase 3 Trial of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Receiving Concurrent Definitive Chemoradiotherapy (KEYNOTE 975)

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 19 Jul 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pembrolizumab (Primary) ; Cisplatin; Fluorouracil; Folinic acid; Levofolinic acid; Oxaliplatin
Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer; Squamous cell cancer
Focus Registrational; Therapeutic Use
Acronyms KEYNOTE 975; MK-3475-975/KEYNOTE-975
Sponsors Merck Sharp & Dohme; Merck Sharp & Dohme Corp.

12 Jul 2024 Planned number of patients changed from 700 to 703.
16 Apr 2024 Planned End Date changed from 15 Apr 2027 to 1 Feb 2027.
16 Apr 2024 Planned primary completion date changed from 15 Apr 2027 to 1 Feb 2027.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com